LAPTM4B‑35 protein is a weak tumor‑associated antigen candidate

Shi,Guilan; Zhou,Chunxia; Wang,Dongmei; Ma,Wenbo; Zhang,Shuren

doi:10.3892/etm.2013.1427

LAPTM4B‑35 protein is a weak tumor‑associated antigen candidate

Authors:
- Guilan Shi
- Chunxia Zhou
- Dongmei Wang
- Wenbo Ma
- Shuren Zhang
View Affiliations

Affiliations: Department of Immunology, Zibo Vocational Institute, Zibo, Shandong 255314, P.R. China, Department of Immunology, Cancer Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100021, P.R. China
Published online on: November 26, 2013 https://doi.org/10.3892/etm.2013.1427
Pages: 491-495

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lysosome‑associated protein transmembrane 4β (LAPTM4B) is a gene that has been indicated to be involved in cancer. It is located at chromosome 8q22 and is composed of seven exons and six introns. LAPTM4B encodes two protein isoforms: LAPTM4B‑35 and LAPTM4B‑24. LAPTM4B‑35 is markedly upregulated and LAPTM4B‑24 is downregulated in several types of cancer. LAPTM4B‑35 is 91 amino acids (N91) longer than LAPTM4B‑24 at the N‑terminus. In the present study, western blotting, enzyme‑linked immunosorbent spot analysis and the B16F10-N91 tumor bearing-mice experiments were used to evaluate whether the overexpression of N91 indicates its potential as a candidate tumor‑associated antigen. The results revealed that N91 was expressed in a wide range of normal mouse tissues and human peripheral blood mononuclear cells, with varying expression levels. The weak immunogenicity of N91 protein suggested it was a weak candidate antigen; however, the N91 protein was associated with cell proliferation.

View Figures

View References

1	Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM and Schlom J: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 87:982–990. 1995. View Article : Google Scholar
2	Palermo B, Del Bello D, Sottini A, et al: Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. Cancer Res. 70:7084–7092. 2010. View Article : Google Scholar
3	Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ and Kast WM: Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res. 56:3782–3787. 1996.PubMed/NCBI
4	Meng F, Song H, Luo C, et al: Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer. 117:2652–2658. 2011. View Article : Google Scholar : PubMed/NCBI
5	Xiao M, Jia S, Wang H, Wang J, Huang Y and Li Z: Overexpression of LAPTM4B: an independent prognostic marker in breast cancer. J Cancer Res Clin Oncol. 139:661–667. 2013. View Article : Google Scholar : PubMed/NCBI
6	Meng F, Li H, Zhou R, Luo C, Hu Y and Lou G: LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis. Biomarkers. 18:136–143. 2013. View Article : Google Scholar : PubMed/NCBI
7	Xu Y, Liu Y, Zhou R, et al: LAPTM4B polymorphisms is associated with ovarian cancer susceptibility and its prognosis. Jpn J Clin Oncol. 42:413–419. 2012. View Article : Google Scholar : PubMed/NCBI
8	Shao GZ, Zhou RL, Zhang QY, et al: Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 22:5060–5069. 2003. View Article : Google Scholar : PubMed/NCBI
9	Liu XS, Dyer J, Leggatt GR, et al: Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host. J Immunol. 177:2873–2879. 2006. View Article : Google Scholar : PubMed/NCBI
10	Yang H, Zhai G, Ji X, Xiong F, Su J and McNutt MA: LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma. PLoS One. 7:e349842012.
11	Zhai G, Yan K, Ji X, et al: LAPTM4B allele *2 is a marker of poor prognosis for gallbladder carcinoma. PLoS One. 7:e452902012.
12	Zhou L, He XD, Chen J, et al: Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer. 43:809–815. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kirk CJ, Hartigan-O’Connor D, Nickoloff BJ, et al: T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 61:2062–2070. 2001.PubMed/NCBI
14	Wang W, Epler J, Salazar LG and Riddell SR: Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res. 66:6826–6833. 2006.
15	Parker KC, Bednarek MA and Coligan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 152:163–175. 1994.PubMed/NCBI
16	Gatz SA, Pohla H and Schendel DJ: A PCR-SSP method to specifically select HLA-A*0201 individuals for immunotherapeutic studies. Tissue Antigens. 55:532–547. 2000.PubMed/NCBI
17	Neumann F, Wagner C, Preuss KD, et al: Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4⁺ T cells. Blood. 106:3105–3113. 2005. View Article : Google Scholar : PubMed/NCBI
18	Neumann F, Wagner C, Stevanovic S, et al: Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int J Cancer. 112:661–668. 2004. View Article : Google Scholar : PubMed/NCBI
19	Nolte A, Scheffold C, Slotty J, et al: Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy. J Immunother. 26:257–269. 2003. View Article : Google Scholar : PubMed/NCBI
20	Boon T: Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer. 54:177–180. 1993. View Article : Google Scholar : PubMed/NCBI
21	Rammensee H, Bachmann J, Emmerich NP, Bachor OA and Stevanovic S: SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 50:213–219. 1999. View Article : Google Scholar : PubMed/NCBI
22	Barnea E, Beer I, Patoka R, et al: Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur J Immunol. 32:213–222. 2002. View Article : Google Scholar : PubMed/NCBI
23	Ramakrishna V, Ross MM, Petersson M, et al: Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol. 15:751–763. 2003. View Article : Google Scholar
24	Fairchild PJ and Wraith DC: Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol Today. 17:80–85. 1996. View Article : Google Scholar : PubMed/NCBI
25	Shastri N, Schwab S and Serwold T: Producing nature’s gene-chips: the generation of peptides for display by MHC class I molecules. Annu Rev Immunol. 20:463–493. 2002.
26	Ren XB, Yu JP, Cao S, et al: Antitumor effect of large doses IL-2-activated HLA haploidentical peripheral blood stem cells on refractory metastatic solid tumor treatment. Cancer Biother Radiopharm. 22:223–234. 2007. View Article : Google Scholar
27	Smyth MJ, Godfrey DI and Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2:293–299. 2001. View Article : Google Scholar : PubMed/NCBI